Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How one woman prevented a pharmaceutical disaster

James Essinger and Sandra Koutzenko
Meds
April 28, 2019
54 Shares
Share
Tweet
Share

An excerpt from Frankie: How One Woman Prevented a Pharmaceutical Disaster.

Between September 1960 and November 1961, when the news broke around the world about thalidomide’s responsibility for the birth of deformed babies, Dr. Frances Kelsey — Frankie — of the Food and Drug Administration (FDA) and the Cincinnati drug company Merrell, that was desperate to launch its ten million thalidomide tablets on unsuspecting pregnant mothers in the U.S. who were suffering from morning sickness, were locked in conflict over Merrell’s dissatisfaction with the way Frankie was handling the thalidomide New Drug Application. Despite great provocation, Frankie kept her cool.

As Merrell’s self-imposed March 1960 deadline for launching thalidomide into the blood systems of American women came and went, Merrell senior executive Dr. Joseph Murray’s dreams of bonuses from the success of thalidomide in the US began to evaporate, and he became increasingly annoyed and frustrated with Frankie.

Merrell’s dissatisfaction stemmed not only from her refusal to approve the drug but also from its conviction that Frankie, as a woman, was somehow exceeding her authority in not allowing the male company executives of Merrell to launch on the American market the ten million thalidomide Kevadon tablets they wanted to sell across the nation.

Frankie recalled [in a handwritten memo] that on December 28, 1960, she made a phone call to Murray …

advising him [as Frankie explained] that Merrell’s local representative had only left one copy of some additional material, Dr. Murray claimed this file was meant for my personal attention rather than for inclusion in [the] NDA. So he said he would send an additional copy. I explained to him the delay and confusion entailed by personal submission of material. He urged me to set a conference date in the near future as they were anxious to market Kevadon and it would require them to detail their salesmen etc. I made no commitments.

This was the pattern of the interaction between Merrell and Frankie for the next eleven months; Murray would push, probe, try to persuade Frankie, try to coerce her, instead of seriously looking into her concerns about the thalidomide NDA. He tried pretty much every stratagem and tactic imaginable, except for actual physical assault and direct bribery. But Frankie was not to be pushed, probed, persuaded, coerced, or anything else.

On December 30, 1960, two days after Frankie made this phone call, her husband, Ellis, who had seen some of the supporting evidence for the thalidomide NDA, wrote a memo to his wife with important content relating to her vital work in assessing the thalidomide NDA. While Ellis did not work with Frankie at the FDA, theirs had always been a marriage founded on a deep and shared love of medical and pharmacological matters. Ellis entitled his memo “Comment on information concerning Kevadon submitted by W. F. Merrell Co. December 9, 1960.” His most strident comments are these:

The section entitled “Chemical Comparison of Thalidomide and Glutethimide” is an interesting collection of meaningless pseudoscientific jargon apparently designed to impress chemically unsophisticated readers.

(1) There is no conceivable significance in a distinction between “natural” and “synthetic” precursors to a synthetic chemical. In either case, the final product is “unnatural.”

(2) Selection of one chemical difference between two compounds as the “most important chemical difference” is absurd. What is the “most important” difference between an apple and an orange?

Ellis went to explain in more technical detail how useless he considered a section of the submission entitled “Absorption Studies in Rats With C-14 Labelled Thalidomide.” He says that “the experimental procedure used is either undescribed or inadequate. The data are completely meaningless as presented.” He concludes, “In summary, none of these data is of any value whatsoever, except to demonstrate that all of the drug is not excreted unchanged in the feces.” He goes on to point out that “in the section ‘Pharmacological Comparison Between Thalidomide and Glutethimide’ appears a very unusual claim that thalidomide has no LD.” As he says, “No other substance can make that claim.” What Ellis means is that every substance does have some dosage level that will kill. For example, drinking an extremely excessive amount of water would obviously be fatal, and even chocolate has a fatal dosage level for an adult (a reassuringly high twenty-eight pounds)—assuming anyone could eat even close to that amount and keep it down.

Ellis Kelsey was showing the thalidomide NDA for the piece of amateurishly incompetent drivel it mostly was.

***

A memo written by Frankie on September 26, 1961, provides final and convincing evidence of her concerns about the use of thalidomide in pregnancy, though of course we know by now that this had been something on her mind since May of that year. We have already quoted this memo in the Prologue, but it is so important that it deserves to be quoted here again, in its proper chronological place.

Murray of Merrell called to try and get a deadline set for release of Kevadon. I explained I was concerned about the use of the drug in pregnancy because of the possible effect on a fetus and the lack of mention of objective findings in peripheral neuritis. He [Murray] wondered if he could record changes by phone and then print up the brochures for the October deadline (to get product on market by Christmas) or bring them in and have me OK them. I said neither would be acceptable as misunderstandings inevitably result and that he should submit the materials through the usual channels. I said we would get to it as soon as possible but could give no definite commitment.

Given what was subsequently discovered about thalidomide, there is something macabre in this fresh example of the extreme pushiness of Murray’s behavior. He tries to get past Frankie’s extremely reasonable objections and reservations by phoning her with some information and making clear that he wants to get the product to market by Christmas 1961, presumably as a Christmas present for the moms of the United States.

James Essinger and Sandra Koutzenko are authors of Frankie: How One Woman Prevented a Pharmaceutical Disaster.

Image credit: Shutterstock.com

Prev

How a physician keynote can highlight your conference

April 28, 2019 Kevin 0
…
Next

Seeing the effects of the opioid crisis play out live

April 29, 2019 Kevin 0
…

Tagged as: OB/GYN

Post navigation

< Previous Post
How a physician keynote can highlight your conference
Next Post >
Seeing the effects of the opioid crisis play out live

Related Posts

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 35-year-old woman with constipation

    mksap
  • 3 ways we’ve failed woman who breastfeed

    Joanna Buscemi, PhD
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 60-year-old woman with persistent constipation

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 45-year-old woman with type 2 diabetes mellitus

    mksap
  • It’s time for presidential candidates to debate the safety of pharmaceutical products

    Steven Reznick, MD
  • The dismantling of informed consent is a disaster

    David Penner

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • How chronic illness and disability are portrayed in media and the importance of daily choices for improved quality of life

      Juliet Morgan and Meghan Jobson | Physician
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • Emulating Michael Jordan’s winning mindset: a path to success for health care professionals and entrepreneurs

      Harvey Castro, MD, MBA | Physician
  • Past 6 Months

    • The growing threat to transgender health care: implications for patients, providers, and trainees

      Carson Hartlage | Policy
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • The pros and cons of taking a gap year during medical school

      Med School Insiders | Education, Sponsored
    • A family physician’s journey on the OIG list and the struggle to return to practice [PODCAST]

      The Podcast by KevinMD | Podcast
    • Heartwarming stories of cancer patients teaching us about life and the human spirit

      Johnathan Yao, MD, MPH | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • The meaning of death in medicine: the role of compassionate care in end-of-life patient care

      Ton La, Jr., MD, JD | Physician
    • From skydiving to saving lives: a surgeon’s journey on adversity, passion, and perseverance [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Addressing Burnout in an Invisible Part of the Health Workforce
  • Family-Oriented Sedation Protocol Helps Kids With ASD Manage Routine Healthcare
  • Bariatric Surgery in Kids With Obesity Becoming More Common
  • NT-proBNP for All; Risky Weekend HF Admits; Ticagrelor for Infective Endocarditis?
  • Clinical Challenges: Test Your Knowledge of Dry Eye Disease

Meeting Coverage

  • New Model Aims to Study Intestinal Fibrosis in Crohn's Disease
  • Hypertension Tied to Worse Survival After Surgery for Upper Tract Urothelial Cancers
  • The Role of Amyloid PET in the Management of Alzheimer's Disease
  • New Inflammation Inhibitor Proves Effective and Safe for Dry Eye Disease
  • No Access to Routine Healthcare Biggest Barrier to HPV Vaccination
  • Most Popular

  • Past Week

    • How chronic illness and disability are portrayed in media and the importance of daily choices for improved quality of life

      Juliet Morgan and Meghan Jobson | Physician
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • Emulating Michael Jordan’s winning mindset: a path to success for health care professionals and entrepreneurs

      Harvey Castro, MD, MBA | Physician
  • Past 6 Months

    • The growing threat to transgender health care: implications for patients, providers, and trainees

      Carson Hartlage | Policy
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • The pros and cons of taking a gap year during medical school

      Med School Insiders | Education, Sponsored
    • A family physician’s journey on the OIG list and the struggle to return to practice [PODCAST]

      The Podcast by KevinMD | Podcast
    • Heartwarming stories of cancer patients teaching us about life and the human spirit

      Johnathan Yao, MD, MPH | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • The meaning of death in medicine: the role of compassionate care in end-of-life patient care

      Ton La, Jr., MD, JD | Physician
    • From skydiving to saving lives: a surgeon’s journey on adversity, passion, and perseverance [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How one woman prevented a pharmaceutical disaster
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...